Differentiating therapy in acute myeloid leukemia

Leukemia

Volumn 10, Issue 8, 1996, Pages 1262-1268

  Tallman, M S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AML; APL; ATRA

Indexed keywords

ANTILEUKEMIC AGENT; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CLOTTING DISORDER; CELL DIFFERENTIATION; CLINICAL TRIAL; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETINOIC ACID SYNDROME;

EID: 0029767898     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Sachs L. Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature 1987; 274: 535-538.
2. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci 1980; 77: 2936-2940.
3. Chomienne C, Balitrand N, Degos L, Abita J-P. 1-β-D-arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells. Leukemia Res 1986; 10: 631-636.
4. Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, Gu L, Wang Z. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
5. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
6. Warrell RP, Frankel SR, Miller WH, Sheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1991; 324: 1385-1393.
7. Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, Warrell RP. All-trans retinoic acid for acute promyelocytic leukemia. Ann Intern Med 1994; 120: 278-286.
8. Chen Z, Zue Y, Zhang R, Tao R, Xia X, Li C, Wang W, Zu W, Yao X, Ling B. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
9. Ohno R, Yoshida H, Fukutani H, Naoe T, Ohshima T, Kyo T, Endoh N, Fujimoto T, Kobayashi T, Hiraoka A, Mizoguchi H, Kodera Y, Suzuki H, Hirano M, Akiyama H, Aoki N, Shindo H, Yokomaku S. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 1722-1727.
10. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sadoun A, Tiberghien P, Fegueux N, Daniel MT, Chomienne C, Degos L. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176-2181.
11. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202-1206.
12. Elliot S, Taylor K, White S, Rodwell R, Marlton P, Meagher D, Wiley J, Taylor D, Wright S, Timms P. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992; 79: 1916-1919.
13. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990; 79: 448-453.
14. Bruel A, Benoit G, De Nay D, Brown S, Lunotte M. Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells, a-cis retinoic acid induces apoptosis independent of maturation and bcl 2 expression. Leukemia 1995; 9: 1173-1184.
15. Larson RA, Kondo K, Vardiman JW, Butler AE, Colomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
16. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Talton W, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol 1985; 3; 793-798.
17. Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 1988; 71: 690-696.
18. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-553.
19. Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, Diverio D, Pegoraro L, Avanzi G, Tabilio A, Zangrilli D, Alcalay M, Donti E, Grignani P, Pelicci PG et al. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemia. J Exp Med 1990; 172: 1571-1575.
20. Miller WH Jr, Warrell RP Jr, Frankel SR, Jakubowski A, Gabrilove JL, Muindi J, Dmitrovsky E. Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 1990; 82: 1932-1933.
21. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Roch-ette-Egly C, Gaube M-P, Chambon P, Pelicci PG. Genomic varia-bility and alternative splicing generate multiple PML/RARα tran-scripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemia. EMBO J 1992; 11: 1397-1407.
22. 3). Ann Intern Med 1980; 92: 261 (letter).
23. Golomb HM, Rowley JD, Vardiman JW, Testa JR, Butler A. 'Microgranular' acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980; 55: 253-259.
24. Sun T, Weiss R. Hand-mirror variant of microgranular acute promyelocytic leukemia. Leukemia 1991; 5: 266-269.
25. Tallman MS, Hakimian D, Snower D, Rubin CM, Reisel H, Variakojis D. Basophilic differentiation in acute promyelocytic leukemia. Leukemia 1993; 7: 521-526.
26. Koike T, Tatewaki W, Aoki A, Yoshimoto H, Yagisawa K, Hashimoto S, Furukawa T, Saitoh H, Takahashi M, Li-bo Y, Ying W, Shibata A. Brief report: severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1992; 327: 385-387.
27. Tomonaga M, Yoshida Y, Tagawa M, Jannai I, Kuriyama K, Amenomori T, Yoshioka A, Matsuo T, Nonaka H, Ichimaru M. Cytochemistry of acute promyelocytic leukemia (M3): leukemic promyelocytes exhibit heterogeneous patterns in cellular differentiation. Blood 1985; 66: 350-357.
28. Lemez P. A case of acute promyelocytic leukaemia with 'faggot cells' exhibiting strong alpha-naphthylbutyrate esterase activity. Br J Haematol 1988; 68: 138-139.
29. Corey SJ, Locker J, Oliveri DR, Shekhter-Levin S, Redner RL, Penchansky L, Gollin SM. A non-classical translocation involving 17q12 (retinoic acid receptor α) in acute promyelocytic leukemia (APL) with atypical features. Leukemia 1994; 8: 1350-1353.
30. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH Jr, Zelenetz AD, Willman CL, Chen Z, Chen SJ, Zelent A, Macintyre E, Veil A, Cortes I, Kantarjian H, Waxman S. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083-1094.
31. Guidez F, Huang W, Tong J-H, Dubois C, Balitrand N, Waxman S, Michaux JL, Martiat P, Degos L, Chen Z, Chomienne C. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RARα patient. Leukemia 1994; 8: 312-317.
32. Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik P. The immunophenotype of acute promyelocytic leukemia: an ECOC study. Leukemia 1994; 8: 1108-1112.
33. Rovelli A, Biondi A, Rajnoldi AC, Conter V, Giudici G, Jankovic M, Locasciulli A, Rizzari C, Romitti L, Rossi MR, Schiro R, Tosi S, Uderzo C, Masera G. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol 1992; 10: 1413-1418.
34. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 1992; 80: 582-586.
35. Vahdat L, Maslak P, Miller WH, Eardley A, Heller G. Scheinberg DA, Warrell RP Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis low-dose chemotherapy, PML/RARα and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
36. Biondi A, Rambaldi A, Pandolfi PP, Giudici G, Alcalay M, Lo Coco F, Diverio D, Pogliani EM, Lanzi EM, Mandelli F, Masera G, Barbui T, Pelicci PG. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
37. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Roch-ette-Egly C, Gaube M-P, Chambon P, Pelicci PG. Genomic varia-bility and alternative splicing generate multiple PML/RARα tran-scripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukaemia. EMBO J 1992; 11: 1397-1407.
38. Miller WH Jr, Heller G, Warrell RP Jr. Implications of the PML/RAR-α isoform at presentation and detection of PML/RAR-α by reverse transcription polymerase chain reaction (RT-PCR) in remission of acute promyelocytic leukemia (APL). Blood 1994; 84: 1501 (Abstr.).
39. Fukatani AU II, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S, Takeshita A, Kobayashi S, Kato Y, Shiraishi K, Sasada M, Ohtake S, Murakami H, Kobayashi M, Endo N, Shindo H, Matsushita K, Hasegawa S, Tsuji K, Ueda Y, Tominaga N, Furuya H, Inoue Y, Takeuchi J, Morishita H, Iida H, Leukemia Study Group of the Ministry of Health and Welfare. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia 1995; 9: 1478-1482.
40. Callagher RE, Yun-Ping L, Rao S, Paietta E, Andersen J, Etkind P, Tallman MS, Wiernik PH. Characterization of acute promyelocytic leukemia cases with PML-RARα break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995; 86: 1540-1547.
41. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995; 9: 774-778.
42. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, Guebner G, Bauters F, Fegueux N, Fey M, Sanz M, Lowenberg B, Maloisel F, Auzanneau G, Sadoun A, Gardin C, Bastion Y, Ganser A, Jacky E, Dombret H, Chastang C, Degos L. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
43. Douer D, Koeffler HP. Retinoic acid enhances growth of human early progenitor cells in vitro. J Clin Invest 1982; 69: 1039-1042.
44. Hassan H, Rees J. Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukemic cells. Hematol Oncol 1988; 6: 39-45.
45. Chomienne C, Balitrand N, Degos L, Abita JP. 1-β-D-arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells. Leukemia Res 1986; 10: 631-636.
46. Lishner M, Curtis JE, Minkin S, McCulloch EA. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 1989; 3: 784-788.
47. Imaizumi M, Sato A, Koizumi Y, Inoue S, Suzuki H, Suwabe N, Yoshinari M, Ichinohasama R, Endo K, Sawai T, Tada K. Potentiated maturation with a high proliferating activity of acute promyelocytic leukemia induced in vitro by granulocyte or granulocyte-macrophage colony-stimulating factors in combination with all-trans retinoic acid. Leukemia 1994; 8: 1301-1308.
48. He R, Breitman TR. Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation. Eur J Haematol 1991; 46: 93-100.
49. Chen A, Licht JD, Wu Y, Hellinger N, Scher W, Waxman S. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 1994; 84: 2122-2129.
50. Jakubowski A, Schuster S, Gabrilove J, Maslak P, Raptis G. All-trans retinoic acid plus granulocyte colony-stimulating factor therapy in patients with acute myelogenous leukemia (AML) - a pilot study. Blood 1993; 82: 2144 (abstr.).
51. Venditti A, Stasi R, Del Poeta G, Buccisano F, Aronica G, Bruno A, Pisani F, Caravita T, Masi M, Tribalto M, Simone MD, Avvisati G, Amadori S, Papa G. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of poor prognosis acute myeloid leukemia. Leukemia 1995; 9: 1121-1125.
52. Tallman MS, Miller HJ, Zanzig C, Rademaker A, Gordon L, Hakimian D, Variakojis D, Stiff P, French S, Benson AB III. All-trans retinoic acid (ATRA), low-dose cytosine arabinoside (LDAra-C) and granulocyte colony-stimulating factor (G-CSF) in relapsed and refractory acute myelogenous leukemia (AML): an Illinois Cancer Center Phase Il pilot study. Blood 1994; 84: 311a.
53. Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoan R, Balis FM. Pharmacokinetics of all-trans retinoic acid administered on an intermittent schedule. J Clin Oncol 1995; 13: 1238-1241.
54. Zhao S, Engel H, Mahadevia R, Bole J, Estey E, Andreeff M. Increased expression of CD38 in HL-60, NB4 cell lines cultured with ATRA and leukemia, lymphoma samples treated with liposomal ATRA in vivo. Blood 1994; 84: 203 (abstr.).
55. Sakashita A, Kizaki M, Pakkala S, Schiller G, Tsuruoka N, Tomosaki R, Cameron JF, Dawson MI, Koeffler HP. 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood 1993; 81: 1009-1016.
56. Kizaki M, Ikeda Y, Tanosaki R, Nakajima H, Morikawa M, Sakashita A, Koeffler HP. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-α and retinoid X receptor-α RNA by HL-60 cells. Blood 1993; 82: 3592-3599.
57. Kizaki M, Nakajima H, Mori S, Koike T, Morikawa M, Ohta M, Saito M, Koeffler HP, Ikeda Y. Novel retinoic acid, 9-cis retinoic acid, in combination with all-trans retinoic acid is an effective inducer of differentiation of retinoic acid-resistant HL-60 cells. Blood 1994; 83: 3289-3297.
58. Bollag W, Peck R. Cancer chemotherapy by combinations of retinoids with cytokines and vitamin D analogs: experimental and clinical results. Ann Oncol 1994; 5 (Suppl. 9): S17-S22.
59. 3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol 1988; 40: 449-459.
60. Winkelmann JC, Ward J, Mayeux P, Lacombe C, Schimmenti L, Jerkins RB. A translocated erythropoietin receptor gene in a human erythroleukemia cell line (TF-1) expresses an abnormal transcript and a truncated protein. Blood 1995; 85: 179-185.
61. Miyazaki E, Kohgo Y, Hirayama M, Kawaniehi J, Kato J, Sakamaki S, Niiteu Y. Remission after erythropoietin administration for erythroleukemia - a case study. Blood 1993; 82: 1378-1380.
62. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsch-Ginsberg C. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73: 2946-2952.